10.28.2010 | Nature
The Long Shadow of the Stem-Cell Ruling: US Firms Could Get Left Behind
By John Nolan, Emad Samad, Suy Anne Martins, and Steve Brozak
The recent litigation in the District of Columbia Circuit attempting to suspend the public funding of human embryonic stem cell (hESC) research in the United States also threatens privately funded research. It has created an atmosphere of grave uncertainty among Wall Street investors who now shy away from hESC products, alarmed by the increased risk that stems from protean federal policy and the ambiguous regulatory requirements.
For the full article, click here
